spacer
home > pmps > winter 2002 > containment solutions: solids charging into process vessels
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Containment Solutions: Solids Charging into Process Vessels

Vessel charging in the process plant has long been identified as a major source of dust emission. Now, with increasing use of active pharmaceutical ingredients (APIs) in the processing and manufacturing stages, the need for assured operator protection is increasing the requirement for effective dust containment. The maximum permissible operator exposure level (OEL) considered in this article is 10µg/m3.

What are the Available Options?

Containment during vessel charging falls into two key categories:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Martyn Ryder, Managing Director of Extract Technology
Martyn Ryder is the Managing Director of Extract Technology, part of the Carlisle Life Science Group. He was educated at Leeds Polytechnic in HVAC and Building Services.

In 1981 he founded Extract Technology, a supplier of pharmaceutical dust control and high containment systems, based in Huddersfield, UK.

spacer
Martyn Ryder
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement